MONTREAL, June 20 /CNW/ - ConjuChem Biotechnologies Inc. (TSX: CJB - News) today announced it has completed the enrollment of its phase II trial with DAC(TM):GRF in patients having lipodystrophy associated with HIV. DAC(TM):GRF, a growth hormone therapeutic, is a compound employing the Growth hormone Releasing Factor (GRF) peptide and is being evaluated in a once-weekly dosing regimen.
